Nama's AI scorecard currently rates Ardent Health Hold (5.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ARDT's P/E ratio?

Ardent Health trades at a trailing price-to-earnings ratio of 13.2.

When does ARDT report earnings?

Ardent Health's next scheduled report is on Mar 3, 2027. Analysts expect EPS of $0.34.

What is the ARDT price target?

The median analyst price target from 12 analysts is $13.00, with a range of $11.00 – $14.00.

Is ARDT Shariah compliant?

Nama's AAOIFI-style screen reads Ardent Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Ardent Health (ARDT)

Healthcare · Medical Care Facilities · NYSE

Ardent Health (ARDT) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $2.44B, a trailing price-to-earnings ratio of 13.2 and a free-cash-flow yield of 10.6%. Over the most recent reported fiscal year, revenue grew 6.0% and free cash flow per share grew 90.3%. Nama's AI scorecard rates it Hold, 5.1 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 5.1/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -24.8% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-16.5%

How far the last close sits under the highest price of the past five years.

Market cap	$2.44B
Trailing P/E	13.2
Price / book	1.8
Price / sales	0.4
FCF yield	10.6%
Dividend yield	—
Gross margin	41.2%
Operating margin	4.0%
Net margin	1.2%
Revenue growth (YoY)	+6.0%
Revenue growth (3-yr annual)	+7.2%
EPS growth (YoY)	—
FCF/share growth (YoY)	+90.3%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Medical Care Facilities

ARDT earnings

Next report: Mar 3, 2027 (Q4 2026, EPS estimate $0.34). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$0.38	$0.25	+52.0%	—
Q2 2026	Aug 4, 2026	$0.27	$0.19	+42.1%	$1.62B
Q1 2026	May 5, 2026	$0.30	$0.18	+66.7%	$1.60B
Q4 2025	Mar 4, 2026	$0.36	$0.35	+2.9%	$1.61B

ARDT analyst price target

Median target $13.00 from 12 analysts, ranging $11.00 – $14.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live ARDT data on Nama Insights →

ARDT FAQ

Is ARDT a buy?: Nama's AI scorecard currently rates Ardent Health Hold (5.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ARDT's P/E ratio?: Ardent Health trades at a trailing price-to-earnings ratio of 13.2.
When does ARDT report earnings?: Ardent Health's next scheduled report is on Mar 3, 2027. Analysts expect EPS of $0.34.
What is the ARDT price target?: The median analyst price target from 12 analysts is $13.00, with a range of $11.00 – $14.00.
Is ARDT Shariah compliant?: Nama's AAOIFI-style screen reads Ardent Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.